Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows

Max Gelman

Senior Editor

Cytokinetics CEO Robert Blum disclosed publicly for the first time rumors of a potential buyout that fell through late last year, according to a new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows

Max Gelman

Senior Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Cy­to­ki­net­ics CEO ad­dress­es ac­qui­si­tion ru­mors, says buy­er walked away, SEC fil­ing shows

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Cytokinetics CEO addresses acquisition rumors, says buyer walked away, SEC filing shows